Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-24 pm EDT 		5-day change 1st Jan Change
48.86 USD -0.27% Intraday chart for Bristol-Myers Squibb Company +1.24% -4.77%
Apr. 23 Germany's Evotec appoints Christian Wojczewski as CEO RE
Apr. 23 Novartis Nominates Former Bristol Myers Squibb CEO as New Chair MT

Financials (USD)

Sales 2024 * 45.78B Sales 2025 * 46.27B Capitalization 99.29B
Net income 2024 * -5.66B Net income 2025 * 10.37B EV / Sales 2024 * 3.04 x
Net Debt 2024 * 39.92B Net Debt 2025 * 31.58B EV / Sales 2025 * 2.83 x
P/E ratio 2024 *
-25.5 x
P/E ratio 2025 *
8.82 x
Employees 34,100
Yield 2024 *
4.95%
Yield 2025 *
5.17%
Free-Float 69.13%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Germany's Evotec appoints Christian Wojczewski as CEO RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand MT
Novartis raises targets for 2024 CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares RE
Bristol Myers signs supply agreement with Cellares CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies RE
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating MT
US FDA mandates label updates on CAR-T cancer therapies RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Pathios Therapeutics Limited announced a financing transaction CI
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors CI
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb : Preliminary Q1 2024 Acquired IPRD and Licensing Income Schedule PU
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster BU
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster BU
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PR
More press releases

News in other languages on Bristol-Myers Squibb Company

Actualización de las fuertes variaciones del día: ¡Todas las publicaciones de resultados resumidas aquí!
Les actions en mouvement : OVH, Novartis, SAP ... toutes les publications de résultats résumées ici !
Novartis überrascht mit Zahlen und neuem Präsidenten
Novartis wird nach dynamischem Auftaktquartal optimistischer für 2024
Novartis-Aktien nach Zahlen und erhöhtem Ausblick im Aufwind
More news

Quotes and Performance

1 day+0.17%
1 week+1.24%
Current month-9.90%
1 month-5.91%
3 months-2.51%
6 months-12.75%
Current year-4.77%
More quotes

Highs and lows

1 week
47.62
Extreme 47.615
49.56
1 month
47.62
Extreme 47.615
54.48
Current year
47.58
Extreme 47.58
55.04
1 year
47.58
Extreme 47.58
70.94
3 years
47.58
Extreme 47.58
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 215 M€ +11.68% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.99% 2 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 18 M€ +4.24% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
24-04-24 48.86 -0.27% 16,032,247
24-04-23 48.99 -0.31% 9,153,290
24-04-22 49.14 +0.43% 7,929,534
24-04-19 48.93 +1.30% 10,303,913
24-04-18 48.3 +0.96% 10,917,581

Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
06:59am - Q1 2024 Earnings Release
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
48.86 USD
Average target price
56.2 USD
Spread / Average Target
+15.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-4.77% 99.29B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 321B
ABBVIE INC. Stock AbbVie Inc.
+8.28% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 204B
NOVARTIS AG Stock Novartis AG
+5.01% 199B
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock